4/25
06:24 am
dmra
Damora Therapeutics, Inc. Common Stock (DMRA) was upgraded by Royal Bank Of Canada to "moderate buy".
Medium
Report
Damora Therapeutics, Inc. Common Stock (DMRA) was upgraded by Royal Bank Of Canada to "moderate buy".
4/24
09:00 am
dmra
Damora Therapeutics, Inc. Common Stock (DMRA) is now covered by Royal Bank Of Canada. They set an "outperform" rating and a $40.00 price target on the stock.
Low
Report
Damora Therapeutics, Inc. Common Stock (DMRA) is now covered by Royal Bank Of Canada. They set an "outperform" rating and a $40.00 price target on the stock.
3/30
08:00 am
dmra
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/25
10:00 am
dmra
Damora Therapeutics, Inc. Common Stock (DMRA) is now covered by Evercore Inc. They set an "outperform" rating and a $46.00 price target on the stock.
Medium
Report
Damora Therapeutics, Inc. Common Stock (DMRA) is now covered by Evercore Inc. They set an "outperform" rating and a $46.00 price target on the stock.
3/23
08:00 am
dmra
Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors
High
Report
Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors
3/19
04:10 pm
dmra
Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
Medium
Report
Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights